Patricia Schroeder
Novo Nordisk (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Hemoglobinopathies and Related Disorders, Chemotherapy-induced cardiotoxicity and mitigation, Erythrocyte Function and Pathophysiology, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1(2014)176 cited
- → Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models(2019)142 cited
- → Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor(2014)98 cited
- → Microbial Contamination of Enteral Feeding Solutions in a Community Hospital(1983)82 cited
- → Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape(2018)74 cited
- → Improving Survival of Vulnerable Infants Increases Neonatal Intensive Care Unit Nosocomial Infection Rate(2001)70 cited
- → Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials(2020)52 cited
- → The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity(2003)51 cited
- → Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape(2015)51 cited
- → Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity(2011)48 cited